Dapagliflozin vs Pioglitazone for Fatty Liver Disease

Evidence-Based Treatment Algorithm

The American Gastroenterological Association recommends pioglitazone as the preferred first-line pharmacotherapy for biopsy-proven NASH, based on robust histological evidence showing resolution of steatohepatitis and reversal of advanced fibrosis, with an odds ratio of 3.22 (95% CI: 2.17–4.79; P < .001) and reversal of advanced fibrosis with an odds ratio of 3.15 (95% CI: 1.25–7.93; P = 0.01) 1, 2
Pioglitazone improves liver histology, achieving NASH resolution with an odds ratio of 3.22 (95% CI: 2.17–4.79; P < .001) and reversal of advanced fibrosis with an odds ratio of 3.15 (95% CI: 1.25–7.93; P = 0.01), in five randomized controlled trials 1, 2
The American Association for the Study of Liver Diseases recommends pioglitazone 30-45 mg daily for 18-24 months as the evidence-based regimen for treating NASH 3, 5, 6
Multiple clinical practice guidelines from Gastroenterology, Hepatology, and the Journal of Hepatology recognize pioglitazone's efficacy for treating NASH 1, 2, 5, 6

Pioglitazone has proven efficacy for NASH resolution, necroinflammation reduction, and fibrosis reversal across multiple RCTs, with an average weight gain of 2.7% (approximately 4.7 kg in PIVENS trial) 1, 2, 3, 4
The European Association for the Study of the Liver notes that pioglitazone is contraindicated in decompensated cirrhosis, and should be avoided in patients with known heart failure, history of bladder cancer, or increased risk of bone loss 1, 2, 7
Dapagliflozin can be used in Child-Pugh A and B cirrhosis, though should be avoided in decompensated cirrhosis, according to the American Gastroenterological Association 8, 9

The American Diabetes Association recommends choosing pioglitazone when a patient has biopsy-proven NASH with significant fibrosis (≥F2) requiring maximal histological benefit, and can tolerate weight gain or weight gain can be mitigated with nutritional counseling 1, 2, 5, 6
The European Association for the Study of the Liver suggests choosing dapagliflozin when a patient cannot tolerate pioglitazone side effects, particularly weight gain, or has comorbid heart failure or chronic kidney disease requiring SGLT2 inhibitor benefits 1, 2
The American Heart Association notes that combination therapy with pioglitazone and SGLT2 inhibitors or GLP-1 receptor agonists can prevent weight gain from pioglitazone, leveraging pioglitazone's proven histological benefits while mitigating its primary adverse effect 1, 2, 4